Trial Profile
An International, Randomized, Double-Blind, Placebo-Controlled Study of Valacyclovir for the Suppression of Recurrent Ano-Genital HSV Infections in HIV-Infected Subjects
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Valaciclovir (Primary)
- Indications Herpes genitalis
- Focus Therapeutic Use
- Sponsors GSK
- 12 Oct 2005 New trial record.